KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy.

Robert J Motzer, Manuela Schmidinger, Masatoshi Eto, Cristina Suarez, Robert Figlin, Yanfang Liu, Rodolfo Perini, Yayan Zhang, Daniel Yc Heng

Future Oncol 19(2) 113-121

PMID36752726
PMCIDPMC13248041
DOI10.2217/fon-2022-0802
发表日期2023-02-08
摘要

摘要

The first-in-class, small molecule HIF-2α inhibitor, belzutifan, has demonstrated promising antitumor activity in previously treated patients with clear cell renal cell carcinoma (RCC). HIF-2α also regulates VEGF expression and is involved in resistance to anti-VEGF therapy. This study describes the rationale and design for a randomized, phase III study evaluating efficacy and safety of belzutifan plus the tyrosine kinase inhibitor (TKI) lenvatinib versus the TKI cabozantinib in patients with advanced RCC progressing after anti-PD-1/PD-L1 therapy in the first- or second-line setting or as adjuvant therapy. Considering the unmet need for effective and tolerable treatment of advanced RCC following immune checkpoint inhibitors, belzutifan plus lenvatinib may have a positive benefit/risk profile. Clinical Trial Registration: NCT04586231 (ClinicalTrials.gov).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。